anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Source Note

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 110,355
Current window 72,991-73,020
Pages 3,679
Rows per page 30
Component: Source Noteclear collectionreset all
18 30 60

Component

72,991-73,020 of 110,355

filter-aware
18
Data as of 13 Sep 22. Table lists specific adverse events by grade.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
Includes a timeline of treatments leading up to NVL-520 and radiological evidence of response.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
26
Slide 26 of a clinical presentation.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
The table highlights the progression of resistance mutations and the increasing prevalence of CNS disease as patients move through lines of therapy.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide compares vehicle control against NVL-655 treatment in both bar chart (multiple models) and line chart (PDX model) formats.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
05
The slide uses a timeline-style layout to represent drug development stages.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
08
Includes a molecular pathway diagram and a Western blot image as evidence.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide demonstrates superior tumor volume reduction by NXP800 compared to standard-of-care Cisplatin in both SKOV-3 and TOV-21G models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Includes a patient-derived xenograft (PDX) study workflow diagram and a tumor volume growth curve.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart shows tumor volume reduction over 28 days compared to vehicle control.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
Clinical trial NCT05226507 status update.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The visualization is a standard kinome tree map used in pharmaceutical research to demonstrate drug selectivity.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
Clinical trial identifier NCT05873686 is provided.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
06
The slide uses a numbered list format to categorize the problem into four distinct areas: clinical outcomes, cost/length of stay, reimbursement losses, and readmission penalties.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Problem1 hit
07
Includes medical citations for each claim.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Problem1 hit
08
Includes medical citations at the bottom.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Problem1 hit
09
Includes a list of clinical citations at the bottom.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Solution1 hit
11
Includes citation references and a 'Newly published' callout for the Abington Hospital study.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
13
The slide uses a split-layout to contrast the problem (diuretic resistance) with the solution (ultrafiltration) supported by clinical evidence.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
15
The slide uses a matrix-like layout to categorize market segments by time horizon.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Market Size1 hit
16
The chart is a Kaplan-Meier survival curve showing the impact of fluid overload on patient outcomes.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
18
The slide highlights high survival rates, particularly in the <10kg group which traditionally receives no therapy.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
19
The slide uses a split-pane layout: left side for problem/market context, right side for product solution.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
20
The slide uses a funnel-like visual to aggregate market segments into a total TAM.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
22
The slide uses a color-coded legend to distinguish between clinical, commercial, product, and partnership milestones.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit
04
The slide uses a map to visualize branch density and three rows of KPIs to demonstrate scale, efficiency, and market standing.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Is1 hit
08
The slide uses a dual-chart layout to compare 'Prior Rate Cycle' (2015-2019) vs 'Current Rate Cycle' (2021-2023).Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could BeLoop · Analogy1 hit
10
Includes three combo charts showing historical trends in credit metrics.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could Be1 hit
11
Includes a performance summary table showing CAGR for Share Price and TBVPS.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could Be1 hit
12
Data covers Q2 2019 through Q2 2023.Old Second Bancorp | Investor Conference Presentation Deck | 21 slides · Old Second Bancorp
Conference presentation Investor relations Beat · What Could Be1 hit